Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026

Rhea-AI Summary

Emergent BioSolutions (NYSE: EBS) received a delivery order valued at up to $21.5 million from the U.S. Department of War to supply BioThrax (Anthrax Vaccine Adsorbed) in 2026. The order is placed under Emergent’s existing IDIQ contract W911SR24D0001, led by the Capability Program Executive CBRND in collaboration with the Defense Health Agency. Deliveries will occur in 2026 and the order includes a one-year base period plus two option periods covering 2027 and 2028. The company said the award continues its partnership to provide anthrax vaccination for military personnel at elevated risk.

Positive

• Delivery order worth up to $21.5M for 2026
• Award placed under existing IDIQ contract W911SR24D0001
• Includes a one-year base plus two option years (2027–2028)
• Collaboration with CPE CBRND and Defense Health Agency

Negative

• None.

Key Figures

BioThrax delivery order $21.5 million 2026 supply order from U.S. Department of War under existing IDIQ contract

Price move 5.7% EBS share price change over the last 24 hours prior to this news

52-week range $4.02–$14.06 EBS 52-week low and high before this announcement

Market cap $730,027,500 Equity value before the BioThrax order news

Base period 1 year Initial base period for the 2026 BioThrax delivery order

Option periods 2 years (2027–2028) Two additional option periods included in the order

Shares outstanding 52,519,964 shares Common shares outstanding cited in recent Rule 144 filings

Planned insider sale 104,695 shares Proposed sale under Rule 144 with value $1,336,462.98

Market Reality Check

$12.96 Last Close

Volume Volume 1,038,449 is 1.28x the 20-day average of 809,608, indicating elevated interest ahead of this contract news. normal

Technical Trading above the 200-day MA at 8.11 and about 4.98% below the 52-week high of 14.06, after rising 5.7% on the day.

Peers on Argus

EBS gained 5.7%, while peers showed mixed moves: CGC +8.4%, EOLS +1.95%, ETON +0.18%, KMDA -0.63%, SIGA -0.44%. With peer_momentum scanners showing no coordinated move, this action appears stock-specific to the BioThrax contract order.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 12	FDA manufacturing approval	Positive	-2.6%	FDA cleared Winnipeg site for raxibacumab drug product manufacturing and testing.
Nov 18	Product milestone	Positive	+0.2%	Marked 10-year NARCAN approval anniversary and reiterated naloxone access commitment.
Nov 12	Board change	Neutral	-4.5%	Announced retirement of long-serving director Louis W. Sullivan from the board.
Oct 29	Earnings results	Positive	-0.7%	Q3 2025 revenue beat guidance and profitability improved, with raised full-year outlook.
Oct 28	Survey on threats	Neutral	-2.3%	Released survey showing heightened concern about biological threats and biodefense support.

Pattern Detected

Recent positive catalysts (FDA approval, earnings beat) often saw flat-to-negative next-day moves, so today’s strong gain on contract news contrasts with that pattern.

Recent Company History

Over the last few months, EBS has reported several biodefense- and transformation-related milestones. On Oct 29, 2025, Q3 2025 results beat revenue guidance and raised full-year outlook, yet shares slipped modestly. Subsequent news highlighted rising concern about biological threats, an FDA approval for raxibacumab manufacturing at the Winnipeg site on Dec 12, 2025, and governance changes with Dr. Sullivan’s retirement. Despite these developments, price reactions were often muted or negative, making today’s positive response to a new BioThrax delivery order more supportive of the franchise narrative.

Market Pulse Summary

This announcement details a BioThrax delivery order worth up to $21.5 million for 2026 from the U.S. Department of War under an existing IDIQ contract, with a one‑year base period and options for 2027–2028. It reinforces Emergent’s biodefense role alongside prior FDA approvals and medical countermeasure contracts. Investors may watch how this order contributes to future revenue mix, follow-on government demand for anthrax countermeasures, and any additional contract modifications or options being exercised.

Key Terms

indefinite-delivery/indefinite-quantity financial

"This order is under Emergent’s existing indefinite-delivery/indefinite-quantity (IDIQ) contract..."

An indefinite-delivery/indefinite-quantity (IDIQ) contract is a purchasing agreement used mainly by governments where the buyer commits to buy goods or services over a set time but does not specify exact quantities or delivery dates up front. For investors this matters because an IDIQ can create a steady pipeline of potential orders and recurring revenue like a standing grocery list a store can draw from, while leaving total future sales and timing uncertain.

idiq financial

"This order is under Emergent’s existing indefinite-delivery/indefinite-quantity (IDIQ) contract..."

An IDIQ (Indefinite Delivery/Indefinite Quantity) is a type of government procurement contract that sets terms and maximum limits for buying goods or services over a period without specifying exact delivery dates or quantities up front. For investors, an IDIQ signals a potential steady revenue stream and easier repeat business because it gives a company preferred access to future orders under agreed terms—think of it as a standing shopping account that can generate unpredictable but recurring sales.

anthrax vaccine adsorbed medical

"to supply BioThrax® (Anthrax Vaccine Adsorbed) in 2026."

A vaccine that protects against infection by the bacterium that causes anthrax; “adsorbed” means the active ingredient is attached to a harmless mineral to strengthen and prolong the body’s immune response, like adding a slow-release coating to a medicine. Investors watch it because demand, regulatory approvals, stockpiled government purchases, and safety data can drive sales and contracts in the biodefense and vaccine markets.

AI-generated analysis. Not financial advice.

GAITHERSBURG, Md., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) announced it has received a delivery order valued at up to $21.5 million from the U.S. Department of War to supply BioThrax^® (Anthrax Vaccine Adsorbed) in 2026. This order is under Emergent’s existing indefinite-delivery/indefinite-quantity (IDIQ) contract (W911SR24D0001), led by the Capability Program Executive Chemical, Biological, Radiological and Nuclear Defense (CPE CBRND), previously the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Health Agency.

“As part of our mission to protect and save lives, we’re proud to help protect those who protect us, including our nation’s service members,” said Paul Williams, senior vice president, head of products business, global government and public affairs at Emergent. “We’re pleased to continue our partnership with the U.S. Department of War to supply BioThrax^® to prepare military personnel at high risk of anthrax exposure.”

Deliveries under this order will take place in 2026. This order includes a one-year base period, with two additional option periods for 2027 and 2028.

About BioThrax^® (Anthrax Vaccine Adsorbed) 
BioThrax^® vaccine is indicated for the active immunization for the prevention of disease caused by Bacillus anthracis in persons 18 through 65 years of age. BioThrax^® is approved for (1) pre-exposure prophylaxis of disease in persons at high risk of exposure; and (2) post-exposure prophylaxis of disease following suspected or confirmed Bacillus anthracis exposure, when administered in conjunction with recommended antibacterial drugs. The efficacy of BioThrax^® for post-exposure prophylaxis is based solely on studies in animal models of inhalational anthrax. 

Select Important Safety Information 

Contraindication: Severe allergic reaction (e.g., anaphylaxis) after a previous dose of BioThrax^® or a component of the vaccine. Warnings and Precautions: Latex: The stopper of the vial contains natural rubber latex and may cause allergic reactions in latex sensitive individuals. Pregnancy: Avoid use in pregnancy unless the potential benefit outweighs the potential risk to the fetus. Adverse Reactions: The most common (>10%) local (injection-site) adverse reactions observed in clinical studies were tenderness, pain, erythema, edema, and arm motion limitation. The most common (≥5%) systemic adverse reactions were muscle aches, fatigue, and headache. 

Please see the full Prescribing Information for BioThrax^® for additional safety information. 

Disclaimer: The views and opinions expressed herein regarding any specific commercial products, process, or service by trade name, trademark, manufacturer, or otherwise do not necessarily constitute or imply endorsement, recommendation, or favoring by the United States government and shall not be used for advertising or product endorsement purposes. 

About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify. 

Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com

Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com

FAQ

What did Emergent BioSolutions (EBS) announce on January 8, 2026?

Emergent announced a delivery order of up to $21.5 million from the U.S. Department of War to supply BioThrax in 2026.

Under which contract was the $21.5M BioThrax order placed for EBS?

The order was placed under Emergent’s existing IDIQ contract W911SR24D0001.

When will deliveries for the BioThrax order for EBS occur?

Deliveries are scheduled to take place in 2026 with a one-year base and two option periods for 2027 and 2028.

Which U.S. agencies are involved in the Emergent BioThrax order (EBS)?

The award is led by the Capability Program Executive CBRND in collaboration with the Defense Health Agency.

How large is the 2026 BioThrax delivery order received by EBS?

The delivery order is valued at up to $21.5 million for 2026.

Does the BioThrax order for EBS include options beyond 2026?

Yes; the order includes a one-year base period and two additional option periods covering 2027 and 2028.